GANX

GANX

USD

Gain Therapeutics Inc. Common Stock

$1.660-0.150 (-8.287%)

السعر في الوقت الحقيقي

Healthcare
التكنولوجيا الحيوية
الولايات المتحدة

مخطط الأسعار

Loading Chart...

المقاييس الرئيسية

مقاييس السوق
أساسيات الشركة
إحصاءات التداول

مقاييس السوق

الافتتاح

$1.810

الأعلى

$1.810

الأدنى

$1.660

الحجم

0.57M

أساسيات الشركة

القيمة السوقية

59.7M

الصناعة

التكنولوجيا الحيوية

البلد

United States

إحصاءات التداول

متوسط الحجم

0.68M

البورصة

NGM

العملة

USD

نطاق 52 أسبوعاً

الأدنى $1.41الحالي $1.660الأعلى $2.81

أخبار ذات صلة

Analyst Upgrades

BTIG Reiterates Buy on Gain Therapeutics, Maintains $9 Price Target

BTIG analyst Thomas Shrader reiterates Gain Therapeutics with a Buy and maintains $9 price target.

عرض المزيد
BTIG Reiterates Buy on Gain Therapeutics, Maintains $9 Price Target
Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics with a Buy and maintains $8 price target.

عرض المزيد
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target
GlobeNewswire

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease

BETHESDA, Md., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of

عرض المزيد
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease
Analyst Upgrades

Maxim Group Maintains Buy on Gain Therapeutics, Raises Price Target to $7

Maxim Group analyst Jason McCarthy maintains Gain Therapeutics with a Buy and raises the price target from $5 to $7.

عرض المزيد
Maxim Group Maintains Buy on Gain Therapeutics, Raises Price Target to $7
GlobeNewswire

Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson's Patients at International Congress of Parkinson's Disease and Movement Disorders®

Improvement observed in MDS-UPDRS scores in first 9 participants enrolled; 90-day follow-up continuing in remaining participants Plasma exposures in patients within projected therapeutic range and comparable to

عرض المزيد
Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson's Patients at International Congress of Parkinson's Disease and Movement Disorders®

ابق على اطلاع

تعيين تنبيهات الأسعار، الحصول على تحديثات تحليل الذكاء الاصطناعي وأخبار السوق في الوقت الحقيقي.